Basket | Login | Register


WP4: Development and validation of translatable pharmacodynamic markers (Pre-clinical studies)

Work Packages

Pharmacog Logo

Main Objectives:

  • To identify a biomarker matrix sensitive to pharmacological intervention with compounds currently approved for the treatment of Alzheimer’s Disease suitable to support pre-clinical PK/PD studies
  • To test the sensitivity of the biomarker matrix by conducting studies using pharmacological tool compounds with novel mechanisms of action.
  • To establish mathematical models describing the relationship between drug exposure and biomarker response to support clinical dose predictions
  • To develop and validate the novel touch screen technology as a model with greater higher throughput, sensitivity and. translational capacity compared to traditional cognitive paradigms

WP Leads

Industry Lead: Dr John Atack (J&J) and Dr. Esther Schenker (Servier)

WP Partners:

  • UnivMed, France
  • University of Verona, Italy
  • University of Foggia, Italy
  • Mario Negri Institute, Italy
  • GSK
  • Boeringher
  • Merck
  • Lilly
  • J&J
  • Lundbeck
  • Eisai Ltd



Last Updated: Tuesday 26 April 2011


  • Acknowledgements

    The research leading to these results has received funding from the European Community's Seventh Framework Programme (FP7/2007-2013) for the Innovative Medicine Initiative under Grant Agreement No 115009.
  • Innovative Medicines Initiative
  • European Union
  • European Federation of Pharmaceutical Industries and Associations